

# Rosalind Ramsey-Goldman

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1779004/rosalind-ramsey-goldman-publications-by-year.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

125  
papers

7,891  
citations

33  
h-index

88  
g-index

136  
ext. papers

10,183  
ext. citations

5  
avg, IF

5.12  
L-index

#	Paper	IF	Citations
125	Motivational interviewing intervention for increasing physical activity and improving dietary behaviors: The lupus intervention fatigue trial protocol.. <i>Contemporary Clinical Trials</i> , <b>2022</b> , 114, 106690	2.3	0
124	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 70, 1997-2004	2.4	4
123	Comparative Risk of Incident Coronary Heart Disease Across Chronic Inflammatory Diseases. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 757738	5.4	1
122	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1789-1795	4.7	2
121	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 2293-2302	9.5	2
120	Malignancies in systemic lupus erythematosus <b>2021</b> , 461-467		
119	Disease development and outcome <b>2021</b> , 37-45		
118	Community-Engaged Research: Leveraging Community-Academic Partnerships to Reduce Disparities and Inequities in Lupus Care. <i>Rheumatic Disease Clinics of North America</i> , <b>2021</b> , 47, 109-118	2.4	0
117	Development of a Set of Lupus-Specific, Ambulatory Care-Sensitive, Potentially Preventable Adverse Conditions: A Delphi Consensus Study. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 146-157	4.7	6
116	A View from the past into our collective future: the oncofertility consortium vision statement. <i>Journal of Assisted Reproduction and Genetics</i> , <b>2021</b> , 38, 3-15	3.4	4
115	Malignancy risk and screening <b>2021</b> , 583-598		
114	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 70, 1997-2004	2.4	10
113	A Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified Lupus. <i>ACR Open Rheumatology</i> , <b>2021</b> , 3, 116-123	3.5	3
112	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. <i>Rheumatology</i> , <b>2021</b> , 60, 4737-4747	3.9	5
111	Global epidemiology of systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , <b>2021</b> , 17, 515-532	8.1	29
110	Systematic review of anti-dsDNA testing for systemic lupus erythematosus: A meta-analysis of the diagnostic test specificity of an anti-dsDNA fluorescence enzyme immunoassay. <i>Autoimmunity Reviews</i> , <b>2021</b> , 20, 102943	13.6	4
109	Using Critical Race Theory to Understand Trial Participation Among Black Individuals With Systemic Lupus Erythematosus: A Qualitative Study of Patients and Caregivers. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1387-1395	4.7	1

108	Association of the Systemic Lupus International Collaborating Clinics Frailty Index and Damage Accrual in Long Standing Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2021</b> ,	4.7	1
107	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies.. <i>Lupus Science and Medicine</i> , <b>2021</b> , 8,	4.6	5
106	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). <i>Arthritis Care and Research</i> , <b>2020</b> ,	4.7	2
105	Widening Disparities Among Patients With Rheumatic Diseases in the COVID-19 Era: An Urgent Call to Action. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 1409-1411	9.5	17
104	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 1734-1740	9.5	7
103	Cell-bound complement activation products associate with lupus severity in SLE. <i>Lupus Science and Medicine</i> , <b>2020</b> , 7,	4.6	4
102	Cancer and Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , <b>2020</b> , 46, 533-550.	4	4
101	Differential Associations of Chronic Inflammatory Diseases With Incident Heart Failure. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 489-498	7.9	22
100	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 658-666	9.5	11
99	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1333-1339	2.4	16
98	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 72-81	4.1	21
97	Associations Between Classification Criteria Items in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 1820-1826	4.7	16
96	Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 78-88	9.5	21
95	Factors Associated With Participation in Rheumatic Disease-Related Research Among Underrepresented Populations: A Qualitative Systematic Review. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 1481-1489	4.7	10
94	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 634-640	2.4	35
93	Cell of origin in diffuse large B-cell lymphoma in systemic lupus erythematosus: molecular and clinical factors associated with survival. <i>Lupus Science and Medicine</i> , <b>2019</b> , 6, e000324	4.6	8
92	Varying levels of X chromosome coalescence in female somatic cells alters the balance of X-linked dosage compensation and is implicated in female-dominant systemic lupus erythematosus. <i>Scientific Reports</i> , <b>2019</b> , 9, 8011	4.9	4
91	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1297-1307	9.5	15

90	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , <b>2019</b> , 58, 1259-1267	3.9	5
89	Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 893-902	4.7	46
88	Brief Report: How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 91-98	9.5	60
87	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1151-1159	2.4	344
86	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1400-1412	9.5	488
85	Malignancies in systemic lupus erythematosus: an update. <i>Current Opinion in Rheumatology</i> , <b>2019</b> , 31, 678-681	5.3	3
84	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1010-1012	2.4	4
83	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 721-726	4.1	29
82	Assessing the Concordance of Clinical Classification Criteria for Lupus Between Electronic Health Records and a Physician Curated Registry. <i>Studies in Health Technology and Informatics</i> , <b>2019</b> , 264, 1466-1467	9.5	1467
81	A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus. <i>Human Molecular Genetics</i> , <b>2018</b> , 27, 2392-2404	5.6	22
80	Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 393-396	4.1	23
79	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , <b>2018</b> , 57, 677-687	3.9	20
78	Serum adipokine levels and associations with patient-reported fatigue in systemic lupus erythematosus. <i>Rheumatology International</i> , <b>2018</b> , 38, 1053-1061	3.6	7
77	Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines. <i>Arthritis Research and Therapy</i> , <b>2018</b> , 20, 133	5.7	26
76	Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans. <i>Human Molecular Genetics</i> , <b>2018</b> , 27, 3813-3824	5.6	23
75	Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. <i>Lupus Science and Medicine</i> , <b>2018</b> , 5, e000263	4.6	14
74	Addressing Lupus Health Disparities: The MONARCAS Community and Academic Collaborative Program. <i>Health Equity</i> , <b>2018</b> , 2, 145-151	3.1	5
73	Systemic lupus erythematosus: a case-based presentation of renal, neurologic, and hematologic emergencies. <i>Expert Review of Clinical Immunology</i> , <b>2018</b> , 14, 803-816	5.1	1

72	Managing cancer risk in patients with systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , <b>2018</b> , 14, 793-802	5.1	5
71	Body mass index is negatively associated with telomere length: a collaborative cross-sectional meta-analysis of 87 observational studies. <i>American Journal of Clinical Nutrition</i> , <b>2018</b> , 108, 453-475	7	69
70	Disease Outcomes and Care Fragmentation Among Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 1369-1376	4.7	18
69	Multiple signals at the extended 8p23 locus are associated with susceptibility to systemic lupus erythematosus. <i>Journal of Medical Genetics</i> , <b>2017</b> , 54, 381-389	5.8	7
68	Transancestral mapping and genetic load in systemic lupus erythematosus. <i>Nature Communications</i> , <b>2017</b> , 8, 16021	17.4	171
67	Comment on: Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus. <i>Rheumatology</i> , <b>2017</b> , 56, 1823-1824	3.9	
66	Malignancy in Pediatric-onset Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 1484-1486	4.8	7
65	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. <i>Lupus Science and Medicine</i> , <b>2017</b> , 4, e000187	4.6	10
64	Cell-bound complement activation products in SLE. <i>Lupus Science and Medicine</i> , <b>2017</b> , 4, e000236	4.6	30
63	A review on SLE and malignancy. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2017</b> , 31, 373-396	5.3	34
62	Depression and Progression of Subclinical Cardiovascular Disease in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 5-11	4.7	19
61	Early endosome as a pathogenic target for antiphosphatidylethanolamine antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, 13798-13803	11.5	4
60	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. <i>Arthritis Research and Therapy</i> , <b>2017</b> , 19, 287	5.7	1
59	Candidate Biomarkers for Fatigue in Systemic Lupus Erythematosus: A Critical Review. <i>Current Rheumatology Reviews</i> , <b>2017</b> , 13, 103-112	1.6	3
58	Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 242-52	2.4	8
57	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , <b>2016</b> , 55, 252-62	3.9	210
56	Disease Development and Outcomes <b>2016</b> , 31-37		1
55	Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , <b>2016</b> , 3, e000165	4.6	16

54	Decreased SMG7 expression associates with lupus-risk variants and elevated antinuclear antibody production. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 2007-2013	2.4	12
53	DNA-damaging autoantibodies and cancer: the lupus butterfly theory. <i>Nature Reviews Rheumatology</i> , <b>2016</b> , 12, 429-34	8.1	39
52	Patient-Reported Outcomes in Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , <b>2016</b> , 42, 253-263	2.4	32
51	Malignancy in Systemic Lupus Erythematosus. <i>Current Treatment Options in Rheumatology</i> , <b>2016</b> , 2, 13-20.3	0.3	1
50	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 1932-44	9.5	27
49	Reply. <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 1053-4	4.7	1
48	Standardised incidence ratios (SIRs) for cancer after renal transplant in systemic lupus erythematosus (SLE) and non-SLE recipients. <i>Lupus Science and Medicine</i> , <b>2016</b> , 3, e000156	4.6	7
47	Malignancy incidence in 5294 patients with juvenile arthritis. <i>RMD Open</i> , <b>2016</b> , 2, e000212	5.9	7
46	Identification of a New Susceptibility Locus for Systemic Lupus Erythematosus on Chromosome 12 in Individuals of European Ancestry. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 174-83	9.5	15
45	Lupus Risk Variant Increases pSTAT1 Binding and Decreases ETS1 Expression. <i>American Journal of Human Genetics</i> , <b>2015</b> , 96, 731-9	11	31
44	Treatment Algorithms in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2015</b> , 67, 1237-1245.7	4.7	67
43	Genetic associations of leptin-related polymorphisms with systemic lupus erythematosus. <i>Clinical Immunology</i> , <b>2015</b> , 161, 157-62	9	8
42	Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 2288-95	4.1	58
41	The IRF5-TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share. <i>Human Molecular Genetics</i> , <b>2015</b> , 24, 582-96	5.6	57
40	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1706-13	2.4	250
39	Self-reported and objectively measured physical activity in adults with systemic lupus erythematosus. <i>Arthritis Care and Research</i> , <b>2015</b> , 67, 701-7	4.7	22
38	Malignancies in systemic lupus erythematosus: a 2015 update. <i>Current Opinion in Rheumatology</i> , <b>2015</b> , 27, 454-60	5.3	54
37	Lupus risk variants in the PDK1 locus alter B-cell receptor internalization. <i>Frontiers in Genetics</i> , <b>2014</b> , 5, 450	4.5	22

36	Lymphoma risk in systemic lupus: effects of disease activity versus treatment. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 138-42	2.4	83
35	Systemic lupus erythematosus and malignancies: a review article. <i>Rheumatic Disease Clinics of North America</i> , <b>2014</b> , 40, 497-506, viii	2.4	19
34	Alpha-chlorofatty Acid and coronary artery or aorta calcium scores in women with systemic lupus erythematosus. A pilot study. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 1834-42	4.1	3
33	Adverse pregnancy outcomes and subsequent risk of cardiovascular disease in women with systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , <b>2014</b> , 1, e000024	4.6	7
32	Dialogue: what can we learn about the relationship between systemic lupus erythematosus and haematological malignancies from linking disease registries?. <i>Lupus Science and Medicine</i> , <b>2014</b> , 1, e000058	4.6	1
31	Risk factors in the progression of subclinical atherosclerosis in women with systemic lupus erythematosus. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 1177-85	4.7	34
30	Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. <i>Lupus Science and Medicine</i> , <b>2014</b> , 1, e000056	4.6	54
29	Two functional lupus-associated BLK promoter variants control cell-type- and developmental-stage-specific transcription. <i>American Journal of Human Genetics</i> , <b>2014</b> , 94, 586-98	11	49
28	Cancer risk in systemic lupus: an updated international multi-centre cohort study. <i>Journal of Autoimmunity</i> , <b>2013</b> , 42, 130-5	15.5	194
27	Cancer risk in childhood-onset systemic lupus. <i>Arthritis Research and Therapy</i> , <b>2013</b> , 15, R198	5.7	17
26	Relation of carotid intima-media thickness and plaque with incident cardiovascular events in women with systemic lupus erythematosus. <i>American Journal of Cardiology</i> , <b>2013</b> , 112, 1025-32	3	69
25	Telomere length in patients with systemic lupus erythematosus and its associations with carotid plaque. <i>Rheumatology</i> , <b>2013</b> , 52, 1101-8	3.9	6
24	Non-lymphoma hematological malignancies in systemic lupus erythematosus. <i>Oncology</i> , <b>2013</b> , 85, 235-40	3.6	24
23	American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. <i>Arthritis Care and Research</i> , <b>2012</b> , 64, 797-808	4.7	863
22	Fatigue in systemic lupus erythematosus. <i>International Journal of Clinical Rheumatology</i> , <b>2012</b> , 7, 217-227	7.5	51
21	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 2677-86		2688
20	Biologics use in sle in 23 centers [Data from the international registry for biologics in SLE. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, A9.1-A9	2.4	1
19	Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). <i>Arthritis Care and Research</i> , 2011, 63 Suppl 11, S37-46	4.7	132

18	Fatigue in systemic lupus erythematosus and rheumatoid arthritis. <i>PM and R</i> , <b>2010</b> , 2, 384-92	2.2	21
17	25-hydroxyvitamin D and cardiovascular risk factors in women with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 61, 1387-95		91
16	Cancer screening in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2006</b> , 33, 45-9	4.1	40
15	Exploring the links between systemic lupus erythematosus and cancer. <i>Rheumatic Disease Clinics of North America</i> , <b>2005</b> , 31, 387-402, viii-ix	2.4	25
14	Revisiting the issue of malignancy risk in systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , <b>2005</b> , 7, 476-81	4.9	7
13	Does hormone replacement therapy affect disease activity in patients with systemic lupus erythematosus?. <i>Nature Clinical Practice Rheumatology</i> , <b>2005</b> , 1, 72-3		1
12	Systemic lupus erythematosus measures: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Measure (SLEDAI), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology-Damage Index (SLICC/ACR-DI; SDI). <i>Arthritis and Rheumatism</i> , <b>2003</b> , 49, S225-S233		15
11	Malignancy and systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , <b>2002</b> , 4, 351-8	4.9	37
10	The rate and pattern of organ damage in late onset systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2002</b> , 29, 913-7	4.1	71
9	Association of osteoporosis and cardiovascular disease in women with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2001</b> , 44, 2338-41		24
8	The Lupus Foundation as an additional source for case ascertainment: Developing a community-based Lupus registry. <i>Arthritis and Rheumatism</i> , <b>2000</b> , 13, 137-140		1
7	A pilot study on the effects of exercise in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2000</b> , 13, 262-9		65
6	Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options?. <i>Drug Safety</i> , <b>1998</b> , 19, 389-410	5.1	52
5	The influence of systemic lupus erythematosus on fetal development: Cognitive, behavioral, and health trends. <i>Journal of the International Neuropsychological Society</i> , <b>1997</b> , 3, 370-376	3.1	51
4	Optimum Use of Disease-Modifying and Immunosuppressive Antirheumatic Agents During Pregnancy and Lactation. <i>BioDrugs</i> , <b>1996</b> , 5, 40-58		6
3	Ethnicity and access to care in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>1996</b> , 9, 492-500		9
2	Rapidly progressive cutaneous vasculitis in a patient with chronic myelomonocytic leukemia. <i>American Journal of Hematology</i> , <b>1995</b> , 50, 310-2	7.1	5
1	Incidence of systemic lupus erythematosus. Race and gender differences. <i>Arthritis and Rheumatism</i> , <b>1995</b> , 38, 1260-70		319



